Lancet Oncology

Published by: Elsevier Science, Inc.  

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Ilson
    Ilson
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Drilon
    Drilon
  7. Tap
    Tap
  8. Aghajanian
    Aghajanian
  9. Janjigian
    Janjigian
  10. Postow
    Postow

Groups

  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (180)
  3. Genitourinary Oncology Service (49)
  4. Hematologic Malignancies, Division of (42)
  5. Gastrointestinal Oncology Service (39)
  6. GSK Faculty (30)
  7. Thoracic Oncology (29)
  8. Center for Hematologic Malignancies (26)
  9. Melanoma and Immunotherapeutics Service (25)
  10. Survivorship Research (20)
Search Within
  1. "Department of Medicine"
Formats
  1. Journal Article (198)
  2. Editorial (8)
  3. Correspondence (6)
  4. Guidelines (4)
  5. Review (1)
Groups
  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (180)
  3. Genitourinary Oncology Service (49)
  4. Hematologic Malignancies, Division of (42)
  5. Gastrointestinal Oncology Service (39)
  6. GSK Faculty (30)

More Groups

People
  1. Robert Motzer (18)
  2. Howard Scher (14)
  3. David Ilson (12)
  4. Gregory Riely (11)
  5. Jedd Wolchok (11)
  6. Ghassan Abou-Alfa (9)

More People

Years
  1. 2024 (4)
  2. 2023 (12)
  3. 2022 (19)
  4. 2021 (21)
  5. 2020 (16)
  6. 2019 (21)

More Years

Publishers
  1. Elsevier Science, Inc. (217)

Results (217)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    Journal Article

    Smit, E. F.; Felip, E.; Uprety, D.; Nagasaka, M.; Nakagawa, K.; Paz-Ares Rodríguez, L.; Pacheco, J. M.; Li, B. T.; Planchard, D.; Baik, C.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Review

    Browne, I. M.; André, F.; Chandarlapaty, S.; Carey, L. A.; Turner, N. C.
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial
    Journal Article

    Mahadeo, K. M.; Baiocchi, R.; Beitinjaneh, A.; Chaganti, S.; Choquet, S.; Dierickx, D.; Dinavahi, R.; Duan, X.; Gamelin, L.; Ghobadi, A.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study
    Journal Article

    Shitara, K.; Rha, S. Y.; Wyrwicz, L. S.; Oshima, T.; Karaseva, N.; Osipov, M.; Yasui, H.; Yabusaki, H.; Afanasyev, S.; Park, Y. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): A single-arm, multicentre, phase 2 trial
    Journal Article

    Albiges, L.; Gurney, H.; Atduev, V.; Suarez, C.; Climent, M. A.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Stus, V.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study
    Journal Article

    Pant, S.; Schuler, M.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Minchom, A.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Spotlight: Preoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma
    Editorial

    Ilson, D.
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study
    Journal Article

    Harding, J. J.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla, T.; Xie, F.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study
    Journal Article

    Van Cutsem, E.; di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J.; Chao, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save

    • Lancet Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 The Lancet Publishing Group
    Lancet Oncology 1470-2045 Elsevier B.V.
    Lancet Oncology 14702045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Inc.
    Lancet Oncology 14702045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 0094-0143 Unknown
    Lancet Oncology 0732-183X Unknown
    Lancet Oncology 1089-9472 Unknown
    Lancet Oncology 0938-7994 Unknown
    Lancet Oncology 2314-6133 Unknown
    Lancet Oncology 2152-2650 Unknown
    Lancet Oncology 1471-2407 Unknown
    Lancet Oncology 1470-2045 Elsevier Science, Inc.
    Lancet Oncology 1470-2045 Unknown
    Lancet Oncology 1470-2045 The Lancet Publishing Group
    Lancet Oncology 14702045 Elsevier Inc.
    Lancet Oncology 14702045 Unknown
    The Lancet Oncology 1470-2045 Elsevier Science, Inc.
    The Lancet Oncology 14745488 Elsevier Inc.
    The Lancet Oncology 14745488 Elsevier Inc.
    The Lancet Oncology 14745488 Unknown
    The Lancet Oncology 1474-5488 Elsevier Inc.
    The Lancet Oncology 14702045 Elsevier Inc.
    The Lancet Oncology 14702045 Unknown
    The Lancet Oncology 1470-2045 Elsevier Inc.
    The Lancet. Oncology 1474-5488 Unknown
    The Lancet. Oncology 14745488 Unknown